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Abstract
Objectives. Modern treatment of RA includes the use of biologics. Their cost is high and comparison
between different treatment strategies is needed.
Method. Direct medical costs of RA in France were evaluated based on expert opinion. Then, simulation–
decision analytical models were developed to assess four biologic treatment sequences over 2 years
in patients failing to respond to at least one anti-TNF agent. Effectiveness was expressed in theoretical
expected number of days (TEND) in remission or low disease activity [low disease activity score (LDAS)]
based on DAS-28 scores.
Results. Direct medical costs of RA in France (excluding the cost of biologics) were estimated at E905
(S.D. 263) for 6 months and E696 (S.D. 240) for each subsequent 6 months (P< 0.001) for patients achiev-
ing LDAS and E1215 for 6 months (S.D. 405) for patients not achieving LDAS. Based on LDAS criteria,
using abatacept after an inadequate response to the first anti-TNF agent (etanercept) appeared signifi-
cantly (P<0.01) more efficacious over a 2-year period (102 TEND) compared with using rituximab at a
6-month re-treatment interval (82 TEND). Mean cost-effectiveness ratios showed significantly lower costs
(P< 0.01) per TEND with abatacept as second biologic agent (E278) compared with rituximab (E303).
After an inadequate response to two anti-TNF agents, using abatacept also appeared significantly more
efficacious than an anti-TNF agent (P< 0.01). All comparisons were confirmed when using remission
criteria instead of LDAS.
Conclusion. Advanced simulation models based on clinical evidence and medical practice appear to be a
promising approach for comparing cost-effectiveness of biologic strategies in RA.
Key words: Rheumatoid arthritis, Cost-effectiveness, Abatacept, Rituximab, Modelling.
Introduction
RA causes progressive destruction of the joints and
serious functional disability, and is associated with a con-
siderable socio-economic burden [1]. RA prevalence
varies across different European countries and popula-
tions. For France, RA prevalence is 0.31%, with a
greater prevalence among women (0.51%; 0.09% in
men) [2]. Considering patient variability in prevalence
and response to treatment, RA requires continuous mon-
itoring and adjustment of treatment strategies against
disease progression.
While the economic impact of RA is substantial,
few studies have evaluated the direct medical costs
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associated with RA in France. One recent estimate of
annual direct costs in RA reached E4000 in France [3].
As RA progresses, patients experience increasing func-
tional impairment that may lead to work disability and
lost wages [4, 5], resulting in significant indirect costs
estimated to be twice as high as direct costs [6]. RA
being a chronic condition with significant economic
impact, there is a need to evaluate the clinical effective-
ness of various treatment strategies, and the cost and
cost-effectiveness of innovative therapies vs existing
treatment regimens.
The treatment of RA is complex and requires different
drugs used in combination or in sequence in the case of
an insufficient response or intolerance to a previous ther-
apy. Clinical and economic estimates are further compli-
cated by the need for continuous adjustment of treatment
regimens. When NSAIDs, corticosteroids or traditional
DMARDs are no longer efficacious due to disease pro-
gression, further treatment options for RA may include
biological agents. TNF antagonists (anti-TNF agents) are
used as first biological option and are often prescribed in
a sequential manner (‘cycling’) in the case of an insuffi-
cient response or intolerance to a first anti-TNF agent.
However, there are no randomized controlled clinical
trials (RCTs) confirming the overall effectiveness of
anti-TNF agents used in a sequential manner in anti-TNF
inadequate responders. Hence, clinicians may elect to
use alternative treatment strategies [7, 8], including new
biological agents that exhibit a different mechanism of
action from anti-TNF agents, and which have been stud-
ied in anti-TNF-refractory patients.
Some reasons for such scarcity of comparative clinical
data are the very high costs of implementing complex
protocols that require monitoring a large number of
patients in the long term. Sophisticated modelling tech-
niques allow these problems to be circumscribed by gen-
erating valid hypothetical data based on existing clinical
evidence, validated expert assumptions and current med-
ical practice in a given country. The modelling approach
uses a mathematical language to compare various treat-
ment strategies as ‘virtual’ head-to-head clinical trials.
Informative results, such as medium- or long-term RA
treatment costs, effectiveness and cost-effectiveness of
various sequential biological strategies can thus be gen-
erated ‘in silico’ when ‘in vivo’ is not practicable [9, 10].
The use of simulation modelling in RA treatment is becom-
ing increasingly common in clinical and economic assess-
ments in the USA, Canada and Europe [11–13].
The objective of this cost-effectiveness model was
to compare costs, effectiveness and cost-effectiveness
of different biological sequential strategies in France in
patients with moderate to severe active RA and an insuf-
ficient response to at least one anti-TNF agent.
Methods
Costs
French RA direct medical costs were derived from a stan-
dard costing approach performed with a panel of three
expert clinicians highly experienced in RA management
(A.S., L.G. and P.G.). Four categories of disease activity
were defined according to 28-joint disease activity score
(DAS-28) thresholds: remission (DAS-28< 2.6), no remis-
sion (DAS-2852.6), low DAS (LDAS: DAS-2843.2) and
no-LDAS representing moderate to high activity state
(DAS-28> 3.2). Direct medical costs were estimated for
6 months according to standard medical practice. The
expert panel described eight RA resource utilization
items of RA medical management in France, according
to national clinical guidelines: medical visits, laboratory
tests, hospitalization, imaging, physiotherapy, nursing,
adaptive aids and transportation. Using a standard cost-
ing approach, CIs of each resource utilization item were
derived from frequency ranges defined by clinical experts
for each disease activity category (remission, LDAS and
moderate to high disease activity). Using a national payer
perspective, unit costs were derived from published
national tariffs (for drug costs: Journal Officiel de la
Re´publique Franc¸aise, for other costs: tariffs from the
French National sick funds) [14, 15]. The experts consid-
ered that the cost of remission or LDAS would vary over
time (first and subsequent 6-month periods). Unit costs
from the national payer perspective were collected and
simulated using distribution ranges for each item.
For each disease activity category (remission, LDAS
and moderate to high disease activity), total management
costs were calculated using resource utilization items,
costs and frequency. Each item costs (for example,
X-ray costs or nurse visit costs) were expressed from
a minimum to a maximum value, according to tariff
ranges in the French healthcare system, using a uniform
distribution. Similarly, each item frequency (for example,
number of X-rays in 6 months or number of nurse visits in
6 months) was expressed using a minimum and maximum
value (based on medical practice variability in France) and
uniform distribution (except for hospitalization which, in
agreement with clinical experts, was programmed using
a triangular distribution, i.e. using three parameters: min-
imum, most likely value and maximum).
A sub-simulation model was carried out to compute
specific distributions of each resource item. All costs
were expressed in 2008 values. Biological drug costs
were calculated based on 2008 French price lists
(Journal Officiel de la Re´publique Franc¸aise) and recom-
mended dosing.
Effectiveness
Two clinically relevant effectiveness end-points aligned
with RA treatment goals were used: LDAS and remission.
Effectiveness estimates of biological therapies in anti-TNF
inadequate responders were derived directly from pub-
lished clinical trials at the time of model development.
For each drug, data from randomized controlled trials
were used if they reported DAS status at 6 months; if
unavailable, other study designs were sought. Thus, the
abatacept trial in treatment of anti-TNF inadequate
responders (ATTAIN) trial and long-term extension study
were used for abatacept [16, 17], the open-label research
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in active rheumatoid arthritis (ReAct) trial for anti-TNF
agents [18] and the randomized evaluation of long-term
efficacy of rituximab (REFLEX) trial and open-label exten-
sion analysis for rituximab in anti-TNF inadequate respon-
ders [19, 20]. The ATTAIN and REFLEX clinical trials were
deemed comparable in terms of patients’ baseline char-
acteristics (age, gender, disease duration and DAS-28
score). Regarding effectiveness data after an insufficient
response to two anti-TNF agents, clinical data for abata-
cept was derived from specific post-hoc analyses of the
ATTAIN trial [21]. In the absence of published effective-
ness data for infliximab after an insufficient response to
two anti-TNF agents, the results of the ReAct trial, an
open-label study published by Bombardieri et al. [18],
were used as best surrogate evidence. Although the
ReAct study specifically concerns adalimumab, the
results correlate with those of the Karlsson et al. study
[22] that studied treatment response to anti-TNF switches,
regardless of the anti-TNF agents used.
Regarding rituximab re-treatment intervals, most of the
patients who received additional courses in rituximab RA
clinical trials (where the need for repeated courses was at
physician’s discretion based on specific response crite-
ria), did so 24 weeks after the previous course and none
were re-treated sooner than 16 weeks (Rituximab US
Product monograph). The model assumed a sustained
DAS-28 response over time; the rituximab re-treatment
interval was, therefore, set at 6 months for the purpose
of this simulation model. A recent analysis of the DAS-28
reduction from baseline with rituximab suggested that
the DAS-28 reduction appears intermittent and depend-
ent on re-treatment intervals [23]. Whereas a 6-month
re-treatment interval was suggested in the literature [24],
in daily practice, the optimal interval for subsequent ritux-
imab treatment courses remains at the discretion of the
physician. To reflect potential variations in real life prac-
tice, and the French Club Rhumatismes et Inflammation
(CRI) recommendations [25], which suggest that
re-treatment should be recommended only 524 weeks
after the first infusion [25], a 9-month re-treatment interval
was simulated as sensitivity analysis and is presented in
the ‘Results’ section.
Assuming comparable patient populations, the percent-
ages of patients achieving LDAS and remission at each
simulated 6-month time point were used to populate the
model over a 2-year time horizon.
Overall effectiveness was expressed in theoretical
expected number of days (TEND) in remission or LDAS
for each sequence over 2 years, which is the product of
success rates (remission or LDAS) by the number of days
in success during each simulation pathway.
Model structure
Using a 2-year time horizon over four 6-month treatment
intervals, four biological strategies were simulated to
reflect sequential use of biological agents. The model con-
siders etanercept as the first anti-TNF agent most often
used in France based on medical practice and market
research studies. Two strategies (Sequences S1 and S2)
assumed 0% success after the first anti-TNF agent
(etanercept), because these simulations focused on a pop-
ulation of inadequate responders to a first anti-TNF agent.
After switching to a second agent (abatacept in Sequence
S1 or rituximab in Sequence S2), the same treatment was
maintained as long as it was efficacious (i.e. for achieving
LDAS or remission). The decision to switch biological ther-
apy following an insufficient response was allowed at
each 6-month time point. Figure 1 presents the general
structure of Sequence S1 using remission as the effective-
ness criterion.
The two other sequential strategies (Sequences S3 and
S4) assume 0% success of a first (etanercept) and to a
second anti-TNF agent (adalimumab) in order to simulate
situations of insufficient response to two anti-TNF agents
before using a third biological agent (abatacept in
Sequence S3 or infliximab in Sequence S4). The four
sequential biological strategies simulated are described
in Table 1. Each sequence was simulated with one spe-
cific model programmed to generate mean values and s.D.
of costs, effectiveness and mean cost-effectiveness over
2 years. Statistical tests (mean tests) were performed
to calculate potentially significant differences between
Sequence 1 and Sequence 2, and between Sequence 3
and Sequence 4.
FIG. 1 General architecture of the model for Sequence 1 using remission as the effectiveness criterion.
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Results
Results from the simulation models take into account all
probabilities of success/no success at every 6-month time
point for all the branches of the tree for each biological
sequence. Because the model also takes into account
potential failures every 6 months, as well as potential
switches to the next biological agent in case of an insuf-
ficient response to the previous agent, the overall success
rate over 2 years for each biological sequence comprising
multiple successive agents (including all potential treat-
ment switches and success/failure probabilities) is neces-
sarily distinct from published long-term data of each
individual agent.
Direct medical costs
Direct medical costs of RA in France (excluding the cost
of biological therapies, which was calculated separately)
were estimated for disease activity level.
For patients achieving remission, costs were estimated
at E771 (S.D. 199) for the first 6 months and at E511
(S.D. 162) for each subsequent 6 months (P< 0.001). For
patients not achieving remission, costs were estimated at
E1159 for 6 months (S.D. 339).
For patients achieving LDAS, costs were estimated
at E905 (S.D. 263) for the first 6 months and at E696
(S.D. 240) for each subsequent 6 months (P< 0.001). For
patients not achieving LDAS, costs were estimated at
E1215 for 6 months (S.D. 405).
Hence, achieving LDAS or remission was associated
with lower medical costs. Key cost drivers were medical
visits and laboratory tests for patients in remission or
LDAS, and hospitalization and transportation for patients
with moderate to high disease activity.
Total costs, effectiveness and cost-effectiveness
Using direct medical costs, the cost of biological thera-
pies and published effectiveness data for each agent
composing the different sequences, the eight simulation
models generated the following results (Figs 2 and 3).
Success criteria: achieving LDAS. The sequence
representing the use of abatacept after an insufficient
response to a first anti-TNF agent (etanercept) appeared
significantly (P< 0.01) more efficacious over 2 years
(102 TEND, S.D. 1.12) compared with a similar sequence
using rituximab (82 TEND, S.D. 1.2). Corresponding mean
cost-effectiveness ratios showed significantly lower costs
(P< 0.01) per TEND with abatacept used after a first
anti-TNF agent (E278, S.D. 32.9) compared with rituximab
using a 6-month re-treatment interval (E303, S.D. 29.4).
Using a 9-month re-treatment interval for rituximab,
the mean cost-effectiveness ratio was E302 for TEND in
LDAS, assuming a sustained effectiveness with rituximab
between 6 and 9 months.
Following an insufficient response to two anti-TNF
agents (etanercept, and then adalimumab), abatacept
used as a third biological agent that appeared significantly
(P< 0.01) more efficacious over 2 years (63 TEND,
S.D. 15.0) compared with a similar sequence using inflix-
imab (32 TEND, S.D. 1.39). Mean cost-effectiveness ratios
showed significantly lower costs (P< 0.01) per TEND to
achieve LDAS (E473, S.D. 124) with abatacept as the third
biological agent compared with infliximab (E817, S.D. 84).
Success criteria: achieving remission. Using the remis-
sion criterion, the sequence using abatacept after a first
anti-TNF agent (etanercept) appeared significantly
(P< 0.01) more efficacious over 2 years (52 TEND,
FIG. 2 TEND in LDAS or remission over 2 years. S1: Sequence 1 (etanercept–abatacept–adalimumab); S2: Sequence 2
(etanercept–rituximab–adalimumab); S3: Sequence 3 (etanercept–adalimumab–abatacept); S4: Sequence 4 (etanercept–
adalimumab–infliximab).
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TABLE 1 Composition of the four biological treatment
sequences
Sequence
First
biological
option
Second
biological
option
Third
biological
option
S1 Etanercept ! Abatacept ! Adalimumab
S2 Etanercept ! Rituximab ! Adalimumab
S3 Etanercept ! Adalimumab ! Abatacept
S4 Etanercept ! Adalimumab ! Infliximab
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S.D. 0.2) compared with a similar sequence using
rituximab (32 TEND, S.D. 0.2). Corresponding mean cost-
effectiveness showed significantly lower costs (P< 0.01)
per TEND with abatacept used after a first anti-TNF agent
(E526, S.D. 50) compared with rituximab (E742, S.D. 52).
Using a 9-month re-treatment interval for rituximab
resulted in E741 for TEND in remission.
Following an insufficient response to two anti-TNF
agents (etanercept, then adalimumab), abatacept used
as a third biological agent appeared significantly
(P< 0.01) more efficacious over 2 years (21 TEND,
S.D. 9.4) compared with a similar sequence using inflixi-
mab (9 TEND, S.D. 0.3). Mean cost-effectiveness ratios
showed significantly lower costs (P< 0.01) per TEND to
achieve remission (E1521, S.D. 785) with abatacept as
a third biological agent compared with infliximab
(E2677, S.D. 205).
Discussion
The results of our resource utilization assessment
show that RA imposes a substantial economic burden
and that achieving remission is associated with lower
RA medical costs. Importantly, for chronic progressive
diseases requiring long-term treatment, most health
gains and any potential economic benefits are often
most evident in the long term [26]. As a consequence,
the RA field has witnessed an explosion of eco-
nomic studies estimating the long-term effects of RA
treatment strategies. In the context of a medico-economic
evaluation, this requires modelling beyond the clinical trial
duration to project available knowledge and clinical data
into the future. Such projections are known to be more
contentious [27]. This explains why most of these studies
are driven by hypotheses that would ideally need to be
validated in clinical trials, including efficacy scenarios
under different therapeutic regimens and time horizons,
correlations between different parameters, etc.
Based on both LDAS and remission criteria, a treatment
sequence using abatacept straight after an insufficient
response to a first anti-TNF agent (etanercept) appeared
more efficacious over 2 years compared with a similar
biological sequence using rituximab. This is explained by
the observed differences in both LDAS and remission
rates at 6 months in the ATTAIN trial for abatacept and
the REFLEX trial for rituximab. Even if rituximab treatment
is cheaper, this difference in effectiveness impacts mean
cost-effectiveness ratios, which showed lower overall
treatment costs per TEND with abatacept as second bio-
logical agent compared with rituximab. Comparing across
clinical trials is always a difficult task as populations
and methodologies are not necessarily similar. However,
patients’ baseline characteristics of the ATTAIN and
REFLEX trials appear similar. In the present model, data
variability was managed using probabilistic sensitivity
analyses and validated assumptions to integrate data
from heterogeneous sources. Simulation models automat-
ically analyse the effect that variable data inputs have
on the outputs of the modelled system. Since different
biological treatment sequences have not yet been com-
pared in head-to-head clinical trials in RA, simulation
models represent the best approach for comparing vari-
ous strategies by taking into account the uncertainty
inherent to the parameters. This approach is considered
a robust sensitivity analysis (probabilistic sensitivity ana-
lysis), which is recommended in economic modelling to
assess the potential impact of distribution of parameters
on the results [10, 28]. Advanced modelling techniques
provide valuable information that would not be available
to decision makers otherwise (or potentially only at pro-
hibitive cost considering the time and resources that
would be required to conduct extremely complex studies,
making timely decision-making impractical). Potential
concerns about model validity have been addressed
both with the introduction of more transparent methods
FIG. 3 Overall treatment cost per TEND in LDAS or remission (in euros). S1: Sequence 1 (etanercept–abatacept–
adalimumab); S2: Sequence 2 (etanercept–rituximab–adalimumab); S3: Sequence 3 (etanercept–adalimumab–
abatacept); and S4: Sequence 4 (etanercept–adalimumab–infliximab).
Eu
ro
s
0
500
1000
1500
2000
2500
3000
S1 S2 S3 S4
LDAS Remission
S.D. 205
S.D. 32.9 S.D. 29.4 S.D. 124
S.D. 84
S.D. 50
S.D. 52
S.D. 785
www.rheumatology.oxfordjournals.org 737
Cost-effectiveness of biological treatments in RA
and by ensuring that necessary assumptions are consis-
tent with medical practice [29].
Most of the published economic models in RA used a
subjective outcome measurement of ‘Quality Adjusted
Life Years’ [30–33]. This approach assesses utility mea-
surements of patient preferences calibrated between 0
(death) and 1 (full health). This method is subject to a
very active methodological debate in health economics
[34, 35], since final results depend heavily on the tech-
nique used to measure utility [30, 36–38].
Relevant to this analysis, and as a main goal of RA
treatment, tight control of disease activity has been
shown to provide major clinical benefits [39, 40].
Welsing et al. [41, 42] demonstrated the relationship
between a fluctuant DAS and radiological progression in
patients with RA. Consequently, slowing the progression
of joint damage is dependent on achieving and maintain-
ing a constant LDAS. In addition to a clear relationship
between the disease activity and the progression of joint
destruction and functional disability, disease activity is
also correlated with overall costs [43–45]. For these rea-
sons, this innovative cost-effectiveness model is based on
the maintenance of a sustained DAS-28 response over 2
years, by either continuing with an effective biological
agent or switching to another agent in the case of insuffi-
cient response to the previous biological therapy. In addi-
tion, controlling the disease activity also positively affects
the quality of life (QoL). A significant inverse correlation of
DAS-28 score with the physical health and psychological
domains of the World Health Organization (WHO) QoL
assessment has been shown [46, 47].
With the emergence of numerous economic evalua-
tions, some international standardization efforts have
been deployed to come up with more consistent factors to
model clinical and economic outcomes in RA treatment.
Specifically, the OMERACT working group proposed
some guidance for estimating clinical improvement in RA
[29]. In contrast to ‘cost–utility analyses’, this innovative
cost–effectiveness analysis is based on published clinical
evidence and involves only a limited number of assump-
tions, aligned with the OMERACT guidelines in economic
evaluations [27].
As for any model, there are some limitations. First, no
randomized clinical trials assessing treatment switches
are available to provide evidence for the effectiveness
data. Secondly, treatment switches occurred in our
models regardless of the cause. For example, the effec-
tiveness of a second anti-TNF agent would be expected
to be higher if the switch is due to adverse events com-
pared with an inadequate response to a first anti-TNF
agent.
RA being a chronic, debilitating and lifelong disease,
using longer time horizons would allow the consideration
of relevant long-term clinical outcomes and downstream
economic consequences. However, this model was
based on existing clinical evidence at the time of model
development to avoid projecting the effectiveness over
a lifetime, which would have brought more uncertainty
in the absence of longer term clinical evidence. As the
re-treatment interval for rituximab <6 months time
period is not formally established [25], this may theoreti-
cally impact the costing results. However, altering the
re-treatment interval from 6 to 9 months did not signifi-
cantly impact the model results because this concerns a
limited number of patients in the final branches of
the decision tree and also because the model assumed
a sustained effectiveness with rituximab between 6 and
9 months. However, a recent analysis of the DAS-28
reduction from baseline with rituximab suggested an inter-
mittent DAS-28 response between re-treatments [23].
Given the reactivation of RA symptoms between rituximab
re-treatments, a 6-month re-treatment interval for rituxi-
mab is now increasingly suggested in the literature [24].
While this model focuses on achieving LDAS or remis-
sion, it does not incorporate the significant favourable
impact of biological therapies on structural evolution,
long-term disability and improvement in QoL (mental
and physical components). In particular, a significant
inverse correlation of the DAS-28 with physical health
and psychological well-being of the WHO QoL assess-
ment has been shown [46, 47]. The improvement in
patients’ QoL being an important goal of RA treatment,
it should be addressed and considered separately,
based on clinical evidence measured in RCTs. Economic
analyses in RA should also ideally consider total direct
and indirect costs associated with the disease [9]. Given
that RA indirect costs are considerable (i.e. loss of income
due to lost work days, change in employment or salary,
productivity loss and long-term disability), the overall
cost-effectiveness of different biological strategies is
likely to be understated.
In conclusion, this innovative cost-effectiveness simula-
tion model is the first to use LDAS and remission as mea-
surements of effectiveness expressed in natural units of
treatment success, and to compare sequential biological
strategies aligned with RA treatment goals and French
medical practice. This analysis aims at informing the
rheumatology community and health authorities in
France on the cost-effectiveness of different RA biological
strategies, including anti-TNF agents, abatacept and
rituximab, used in sequence in patients with moderate
to severe active RA and an insufficient response to other
DMARDs, including at least one anti-TNF agent.
Advanced simulation models based on clinical evidence
and medical practice appear to be a promising approach
for comparing costs, effectiveness and cost-effectiveness
of complex sequential biological strategies for the man-
agement of moderate to severe active RA.
Rheumatology key messages
. Cost-effectiveness analysis expressed in costs per
clinical outcome is a clinically meaningful robust
approach.
. Biological therapies can be compared using costs
to achieve remission or low disease activity.
. Simulation models are a promising approach to
assess complex RA biological strategies.
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